StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a report released on Monday. The firm set a “sell” rating on the biopharmaceutical company’s stock. NASDAQ:AKTX opened at $1.13 on Monday. Akari Therapeutics has a 1-year low of $1.05 and a 1-year high of $2.74. The firm has a fifty day […]
StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Rating) in a report published on Friday. The firm issued a sell rating on the biopharmaceutical company’s stock. NASDAQ AKTX opened at $1.10 on Friday. Akari Therapeutics has a 52 week low of $1.05 and a 52 week high of $3.20. The stock has […]
Akari’s complement and leukotriene inhibitor, nomacopan, demonstrated improved survival (80% vs. 30%) in a preclinical model of traumaA follow-on program.